GlaxoSmithKline PLC (GSK-N)
NYSE:GSK
37.43
0.07
(0.19%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 2 opinions in the last 12 months.
GlaxoSmithKline PLC (GSK-N) has garnered positive reviews from analysts, highlighting its solid financial foundations and strategic moves in the biopharmaceutical realm. The company is noted for maintaining consistent cash reserves while actively reducing debt, a strategy that resonates well with its long-term stability. Both reviews point to the stock's valuation at 22 times earnings, with ROE figures of 18% and 21% respectively, underscoring its profitability and efficient capital utilization. The analysts express confidence in GSK's initiatives, particularly its partnerships in addressing Parkinson's disease and continued advancements in oncology treatments. With recommended price targets ranging from $40.89 to $45.07 and an attractive yield of approximately 4.5%, the analysts suggest a favorable upside potential that makes GSK an appealing option in the biopharma sector.
This large global biopharma company has reported continued success in a oncology based treatment for a blood cancer effecting 180,000 new patients annually. The company is building cash reserves while debt is retired. It trades at 22x earnings and supports a 21% ROE. We recommend setting a stop-loss at $27, looking to achieve $45 -- upside potential of 26%. Yield 4.5%
(Analysts’ price target is $45.07)They sold their personal care business to generate a lot of capital. They're strong in vaccines, but don't have a strong pipeline of drugs. So, they need to buy other companies to make up for that. Not a high PE and pays a good dividend. The key is what they will do with their capital.
Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some divisions, so now more of a pure pharma company, which has risks. Have to worry about pipeline constantly. JNJ, for example, is more diversified, and that's what he prefers.
Still likes it. They spun off over-the counter and consumer pharmaceuticals like Advil and that's when shares dipped (last fall). He chose it back then to bet on Covid vaccines, but that didn't pan out. But he likes it for that spin off and you get paid a reasonable dividend.
GlaxoSmithKline PLC(GSK-N) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
GlaxoSmithKline PLC(GSK-N) Frequently Asked Questions
What is GlaxoSmithKline PLC stock symbol?
GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N
Is GlaxoSmithKline PLC a buy or a sell?
In the last year, there was no coverage of GlaxoSmithKline PLC published on Stockchase.
Is GlaxoSmithKline PLC a good investment or a top pick?
GlaxoSmithKline PLC was recommended as a Top Pick by on . Read the latest stock experts ratings for GlaxoSmithKline PLC.
Why is GlaxoSmithKline PLC stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is GlaxoSmithKline PLC worth watching?
0 stock analysts on Stockchase covered GlaxoSmithKline PLC In the last year. It is a trending stock that is worth watching.
What is GlaxoSmithKline PLC stock price?
On 2025-04-25, GlaxoSmithKline PLC (GSK-N) stock closed at a price of $37.43.
We reiterate GSK as a TOP PICK. We like that cash reserves are holding steady, despite an aggressive retirement of debt. It trades at 22x earnings and supports a 18% ROE. The solid dividend is backed by a payout ratio under 50% of cash flow. The company is partnering with another pharma to develop Parkinson's disease treatments. We continue to recommend a stop at $27, looking to achieve $41 -- upside potential over 20%. Yield 4.6%
(Analysts’ price target is $40.89)